Literature DB >> 7566362

Affinities of muscarinic drugs for [3H]N-methylscopolamine (NMS) and [3H]oxotremorine (OXO) binding to a mixture of M1-M4 muscarinic receptors: use of NMS/OXO-M ratios to group compounds into potential agonist, partial agonist, and antagonist classes.

N A Sharif1, G W Williams, L M DeSantis.   

Abstract

The relative affinities of various muscarinic drugs in the antagonist ([3H]N-methyl scopolamine ([3H]NMS)) and agonist ([3H]Oxotremorine-m ([3H]OXO-M)) binding assays using a mixture of tissues containing M1-M4 receptor subtypes have been determined. [3H]NMS bound with high affinity (Kd = 25 +/- 5.9 pM; n = 3) and to a high density Bmax = 11.8 +/- 0.025 nmol/g wet weight) of muscarinic receptors. [3H]OXO-M appeared to bind to two binding sites with differing affinities (Kd1 = 2.5 +/- 0.1 nM; Kd2 = 9.0 +/- 4.9 microM; n = 4) and to a different population of binding sites (Bmax1 = 5.0 +/- 0.26 nmol/g wet weight; Bmax2 = 130 +/- 60 nmol/g wet weight). Well known antagonists exhibited high affinity for [3H]NMS binding but a lower affinity for [3H]OXO-M binding. The opposite was true for acetylcholine and other known agonists. However, pilocarpine and McN-A-343 had similar affinities for sites labeled by both radioligands. Using the ratios of antagonist-to-agonist binding affinities, it was possible to group compounds into apparently distinct full agonist (ratios of 180-665; e.g. carbachol, muscarine, OXO-M, OXO-S and arecoline), partial agonist (ratios of 14-132; e.g. McN-A-343, pilocarpine, aceclidine, bethanechol, OXA-22 and acetylcholine) and antagonist (ratios of 0.22-1.9; e.g. atropine, NMS, pirenzepine, methoctramine, 4-DAMP and p-fluorohexahydrosialo-difenidol) classes. These data suggest that the NMS/OXO-M affinity ratios using a mixture of M1-M4 muscarinic receptors may be a useful way to screen and group a large number of compounds into apparent agonist, partial agonist, and antagonist classes of cholinergic agents.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7566362     DOI: 10.1007/BF01705534

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  16 in total

Review 1.  Muscarinic receptors--characterization, coupling and function.

Authors:  M P Caulfield
Journal:  Pharmacol Ther       Date:  1993-06       Impact factor: 12.310

2.  Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: the NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors.

Authors:  S B Freedman; E A Harley; L L Iversen
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

3.  Characterization of the m4 muscarinic receptor Ca2+ response in a subclone of PC-12 cells by single cell flow cytometry. Inhibition of the response by bradykinin.

Authors:  J T Ransom; H M Cherwinski; R E Delmendo; N A Sharif; R Eglen
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

4.  Affinity of muscarinic receptor antagonists for three putative muscarinic receptor binding sites.

Authors:  R E Delmendo; A D Michel; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

5.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

Review 6.  Molecular basis of muscarinic acetylcholine receptor function.

Authors:  J Wess
Journal:  Trends Pharmacol Sci       Date:  1993-08       Impact factor: 14.819

7.  Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists.

Authors:  S Z Wang; E E el-Fakahany
Journal:  J Pharmacol Exp Ther       Date:  1993-07       Impact factor: 4.030

8.  M3 muscarinic receptors on murine HSDM1C1 cells: further functional, regulatory, and receptor binding studies.

Authors:  N A Sharif; Z P To; K H Wong; R E Delmendo; R L Whiting; R M Eglen
Journal:  Neurochem Res       Date:  1995-01       Impact factor: 3.996

9.  Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists.

Authors:  M H Richards; P L van Giersbergen
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

10.  Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding.

Authors:  N A Sharif; E H Wong; D N Loury; E Stefanich; A D Michel; R M Eglen; R L Whiting
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

View more
  4 in total

Review 1.  Ligand binding assays at equilibrium: validation and interpretation.

Authors:  Edward C Hulme; Mike A Trevethick
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Inverse agonist activity of pirenzepine at M2 muscarinic acetylcholine receptors.

Authors:  L Daeffler; F Schmidlin; J P Gies; Y Landry
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 3.  Cholinergic regulation of epithelial ion transport in the mammalian intestine.

Authors:  C L Hirota; D M McKay
Journal:  Br J Pharmacol       Date:  2006-09-18       Impact factor: 8.739

4.  Fluorescence changes reveal kinetic steps of muscarinic receptor-mediated modulation of phosphoinositides and Kv7.2/7.3 K+ channels.

Authors:  Jill B Jensen; John S Lyssand; Chris Hague; Bertil Hille
Journal:  J Gen Physiol       Date:  2009-04       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.